Cinacalcet
- PMID: 32491590
- Bookshelf ID: NBK557658
Cinacalcet
Excerpt
Cinacalcet hydrochloride is classified as a calcimimetic medication approved by the US Food and Drug Administration (FDA) for the management of secondary hyperparathyroidism associated with end-stage kidney disease and primary hyperparathyroidism in cases where surgical intervention is not feasible. Cinacalcet is also used off-label for the treatment of calciphylaxis in patients with advanced kidney disease or undergoing dialysis.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Sekercioglu N, Busse JW, Sekercioglu MF, Agarwal A, Shaikh S, Lopes LC, Mustafa RA, Guyatt GH, Thabane L. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2016 Jul;38(6):857-74. - PubMed
-
- Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis. Pediatr Nephrol. 2019 Jan;34(1):145-154. - PMC - PubMed
-
- Junaid SZS, Patel P, Patel JB. StatPearls [Internet] StatPearls Publishing; Treasure Island (FL): 2024. Feb 24, Cinacalcet. - PubMed
-
- Cetani F, Saponaro F, Marcocci C. Non-surgical management of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):821-835. - PubMed
-
- Takeuchi Y, Takahashi S, Miura D, Katagiri M, Nakashima N, Ohishi H, Shimazaki R, Tominaga Y. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. J Bone Miner Metab. 2017 Nov;35(6):616-622. - PubMed
Publication types
LinkOut - more resources
Full Text Sources